These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37694500)

  • 21. Can changes in renal function predict variations in β-lactam concentrations in septic patients?
    Casu GS; Hites M; Jacobs F; Cotton F; Wolff F; Beumier M; De Backer D; Vincent JL; Taccone FS
    Int J Antimicrob Agents; 2013 Nov; 42(5):422-8. PubMed ID: 23993066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin.
    Delattre IK; Musuamba FT; Verbeeck RK; Dugernier T; Spapen H; Laterre PF; Wittebole X; Cumps J; Taccone FS; Vincent JL; Jacobs F; Wallemacq PE
    Clin Biochem; 2010 Apr; 43(6):589-98. PubMed ID: 20036226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beta-Lactam Antibiotic Therapeutic Drug Monitoring in Critically Ill Patients: A Systematic Review and Meta-Analysis.
    Pai Mangalore R; Ashok A; Lee SJ; Romero L; Peel TN; Udy AA; Peleg AY
    Clin Infect Dis; 2022 Nov; 75(10):1848-1860. PubMed ID: 35731853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.
    Abdul-Aziz MH; Sulaiman H; Mat-Nor MB; Rai V; Wong KK; Hasan MS; Abd Rahman AN; Jamal JA; Wallis SC; Lipman J; Staatz CE; Roberts JA
    Intensive Care Med; 2016 Oct; 42(10):1535-1545. PubMed ID: 26754759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β-lactam therapy.
    Imani S; Buscher H; Day R; Gentili S; Jones GRD; Marriott D; Norris R; Sandaradura I
    Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2171-2175. PubMed ID: 30120647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical application of beta-lactam antibiotic therapeutic drug monitoring in the critical care setting.
    Pai Mangalore R; Peel TN; Udy AA; Peleg AY
    J Antimicrob Chemother; 2023 Oct; 78(10):2395-2405. PubMed ID: 37466209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.
    Roberts JA; Ulldemolins M; Roberts MS; McWhinney B; Ungerer J; Paterson DL; Lipman J
    Int J Antimicrob Agents; 2010 Oct; 36(4):332-9. PubMed ID: 20685085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Barriers and Facilitators in the Clinical Implementation of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: A Critical Review.
    Abdulla A; van den Broek P; Ewoldt TMJ; Muller AE; Endeman H; Koch BCP
    Ther Drug Monit; 2022 Feb; 44(1):112-120. PubMed ID: 34798631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.
    Delattre IK; Musuamba FT; Jacqmin P; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq P
    Clin Biochem; 2012 Jul; 45(10-11):780-6. PubMed ID: 22503878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low attainment to PK/PD-targets for β-lactams in a multi-center study on the first 72 h of treatment in ICU patients.
    Smekal AK; Furebring M; Eliasson E; Lipcsey M
    Sci Rep; 2022 Dec; 12(1):21891. PubMed ID: 36535989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III.
    Lipman J; Brett SJ; De Waele JJ; Cotta MO; Davis JS; Finfer S; Glass P; Knowles S; McGuinness S; Myburgh J; Paterson DL; Peake S; Rajbhandari D; Rhodes A; Roberts JA; Shirwadkar C; Starr T; Taylor C; Billot L; Dulhunty JM
    Crit Care Resusc; 2019 Mar; 21(1):63-68. PubMed ID: 30857514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients.
    Al-Shaer MH; Rubido E; Cherabuddi K; Venugopalan V; Klinker K; Peloquin C
    J Antimicrob Chemother; 2020 Dec; 75(12):3644-3651. PubMed ID: 32910809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beta-lactam exposure and safety in intermittent or continuous infusion in critically ill children: an observational monocenter study.
    Debray A; Callot D; Hirt D; Bille E; Renolleau S; Chouchana L; Tréluyer JM; Oualha M; Béranger A
    Eur J Pediatr; 2023 Mar; 182(3):965-973. PubMed ID: 36422708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum β-lactam concentrations in critically ill patients with cirrhosis: a matched case-control study.
    Lheureux O; Trepo E; Hites M; Cotton F; Wolff F; Surin R; Creteur J; Vincent JL; Gustot T; Jacobs F; Taccone FS
    Liver Int; 2016 Jul; 36(7):1002-10. PubMed ID: 26645828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations.
    Udy AA; Varghese JM; Altukroni M; Briscoe S; McWhinney BC; Ungerer JP; Lipman J; Roberts JA
    Chest; 2012 Jul; 142(1):30-39. PubMed ID: 22194591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic aspects of beta-lactam antibiotic therapy in intensive care unit patients: A one-center experience with TDM.
    Sadilová K; Halačová M; Černý D
    Ceska Slov Farm; 2020; 69(1):17-23. PubMed ID: 32460506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of the DMAIC Lean Six Sigma quality improvement framework to improve beta-lactam antibiotic adequacy in the critically ill.
    Wessel RJ; Rivera CG; Ausman SE; Martin N; Braga SA; Hagy NT; Moreland-Head LN; Abu Saleh OM; Gajic O; Jannetto PJ; Barreto EF
    Int J Qual Health Care; 2024 Jul; 36(3):. PubMed ID: 38955670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. β-lactam antibiotic concentrations during continuous renal replacement therapy.
    Beumier M; Casu GS; Hites M; Seyler L; Cotton F; Vincent JL; Jacobs F; Taccone FS
    Crit Care; 2014 May; 18(3):R105. PubMed ID: 24886826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics/Pharmacodynamics of β-Lactams and Therapeutic Drug Monitoring: From Theory to Practical Issues in the Intensive Care Unit.
    Williams P; Cotta MO; Roberts JA
    Semin Respir Crit Care Med; 2019 Aug; 40(4):476-487. PubMed ID: 31585474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suboptimal Beta-Lactam Therapy in Critically Ill Children: Risk Factors and Outcome.
    Van Der Heggen T; Dhont E; Willems J; Herck I; Delanghe JR; Stove V; Verstraete AG; Vanhaesebrouck S; De Paepe P; De Cock PAJG
    Pediatr Crit Care Med; 2022 Jul; 23(7):e309-e318. PubMed ID: 35426861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.